N-丁基-N2-甲基甘氨酰胺 | 117194-70-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-丁基-N2-甲基甘氨酰胺
• 英文名称: N-Butyl-2-(methylamino)acetamide
• CAS: 117194-70-4
• 化学式: C₇H₁₆N₂O
• mdl: MFCD09864444
• 分子量: 144.21
• InChiKey: YPQBXFWRJLBFDU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• TARGET PROTEIN EED DEGRADATION-INDUCING DEGRADUCER, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATED TO EED, EZH2, OR PRC2, COMPRISING SAME AS ACTIVE INGREDIENT
  申请人：Korea Research Institute of Chemical Technology

  公开号：EP3922632A1

  公开（公告）日：2021-12-15

  The present invention relates to a target protein degradation-inducing Degraducer, a preparation method thereof, and a pharmaceutical composition for preventing or treating diseases related to EED, EZH2, or PRC2 comprising same as an active ingredient. A novel compound represented by formula 1, according to the present invention is a Degraducer compound that induces degradation of a target protein, i.e., embryonic ectoderm development (EED) or polycomb repressive complex 2 (PRC2), utilizing cereblon E3 ubiquitin ligase, von Hippel-Lindau tumor suppressor (VHL) E3 ubiquitin ligase, mouse double minute 2 homolog (MDM2) E3 ubiquitin ligase, and cellular inhibitor of apoptosis protein 1 (cIAP) E3 ubiquitin ligase, wherein the compound has an aspect of remarkably achieving target protein degradation-inducing activity through a ubiquitin proteasome system (UPS), and therefore there is a useful effect in that it is possible to provide a pharmaceutical composition for preventing or treating diseases or conditions related to a target protein, and a functional health food composition for preventing or improving same, comprising said compound as an active ingredient.

  本发明涉及一种靶蛋白降解诱导剂Degraducer，其制备方法以及包含其作为活性成分的用于预防或治疗与EED、EZH2或PRC2相关疾病的药物组合物。根据本发明，由式1表示的一种新化合物是一种Degraducer化合物，通过利用cereblon E3泛素连接酶、von Hippel-Lindau肿瘤抑制因子（VHL）E3泛素连接酶、鼠双分钟2同源物（MDM2）E3泛素连接酶和细胞凋亡抑制蛋白1（cIAP）E3泛素连接酶诱导靶蛋白，即胚胎外胚层发育（EED）或多能复合体抑制2（PRC2）的降解，其中该化合物通过泛素蛋白酶体系统（UPS）显著实现靶蛋白降解诱导活性的方面，因此可以提供一种用于预防或治疗与靶蛋白相关疾病或症状的药物组合物，以及包含所述化合物作为活性成分的功能性保健食品组合物，具有有益效果。
• Multifunctional Supramolecular Hydrogels as Biomaterials
  申请人：Xu Bing

  公开号：US20070224273A1

  公开（公告）日：2007-09-27

  The present invention provides supramolecular hydrogels having a three-dimensional, self-assembling, elastic, network structure comprising non-polymeric, functional molecules and a liquid medium, whereby the functional molecules are noncovalently crosslinked. The functional molecules may be, for instance, anti-inflammatory molecules, antibiotics, metal chelators, anticancer agents, small peptides, surface-modified nanoparticles, or a combination thereof. Applications of the present invention include use of the supramolecular hydrogel, for instance, as a biomaterial for wound healing, tissue engineering, drug delivery, and drug/inhibitor screening.

  本发明提供了一种超分子水凝胶，其具有三维、自组装、弹性、网络结构，包括非聚合的功能分子和液体介质，其中功能分子是非共价交联的。这些功能分子可以是抗炎分子、抗生素、金属螯合剂、抗癌剂、小肽、表面修饰纳米颗粒或其组合。本发明的应用包括使用超分子水凝胶作为生物材料，例如用于伤口愈合、组织工程、药物输送和药物/抑制剂筛选。
• [EN] SMALL MOLECULE DEGRADERS OF PHOSPHATIDYLINOSITOL-5-PHOSPHATE 4-KINASE TYPE 2 AND USES THEREOF<br/>[FR] AGENTS DE DÉGRADATION À PETITES MOLÉCULES DE PHOSPHATIDYLINOSITOL-5-PHOSPHATE 4-KINASE DE TYPE 2 ET LEURS UTILISATIONS
  申请人：DANA FARBER CANCER INST INC

  公开号：WO2022140554A1

  公开（公告）日：2022-06-30

  The present invention relates to bifunctional compounds, compositions, and methods for treating diseases or conditions by modulating (e.g., reducing) the level or activity of at least one of PIP4K2A, PIP4K2B, and PIP4K2C.

  本发明涉及双重功能化合物、组合物和方法，通过调节（例如，降低）PIP4K2A、PIP4K2B和PIP4K2C中至少一种的水平或活性来治疗疾病或病症。
• US3969087A
  申请人：——

  公开号：US3969087A

  公开（公告）日：1976-07-13
• [EN] EPOXIDE INHIBITORS OF CYSTEINE PROTEASES<br/>[FR] INHIBITEURS ÉPOXYDE DE CYSTÉINE PROTÉASES
  申请人：UNIV LELAND STANFORD JUNIOR

  公开号：WO2008042480A2

  公开（公告）日：2008-04-10

  [EN] Provided herein are novel epoxide inhibitors of cysteine proteases, compositions comprising the epoxide inhibitors, and packaged pharmaceuticals. Also provided are methods of inhibiting a papain-family cysteine protease and methods of treating or preventing a disease by administering a composition containing an epoxide inhibitor of the invention. The compositions may be administered in combination with another therapeutic agent.
  [FR] La présente invention concerne de nouveaux inhibiteurs époxyde de cystéine protéases, des compositions contenant ces inhibiteurs époxyde, et des produits pharmaceutiques conditionnés. L'invention concerne également des procédés d'inhibition d'une cystéine protéase appartenant à la famille de la papaïne et des procédés de traitement ou de prévention d'une maladie grâce à l'administration d'une composition contenant un inhibiteur époxyde selon l'invention. Les compositions peuvent être administrées sous forme combinée à un autre agent thérapeutique.